Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma

Paolo Corradini, Michele Cavo, Henk Lokhorst, Giovanni Martinelli, Carolina Terragna, Ignazio Majolino, Pinuccia Valagussa, Mario Boccadoro, Diana Samson, Andrea Bacigalupo, Nigel Russell, Vittorio Montefusco, Claudia Voena, Gosta Gahrton

Research output: Contribution to journalArticlepeer-review

Abstract

Patients in complete clinical remission after myeloablative allogeneic stem cell transplantation (allo-SCT) were enrolled in a longitudinal study to assess the predictive value of molecular monitoring. Using polymerase chain reaction (PCR) for immunoglobulin gene rearrangements it was possible to generate a clone-specific molecular marker in 48 of 70 patients. Of these 48 patients, 16 (33%) attained durable PCR-negativity after transplantation, whereas 13 (27%) remained persistently PCR-positive and 19 (40%) showed a mixed pattern. The cumulative risk of relapse at 5 years was 0% for PCR-negative patients, 33% for PCR-mixed patients, and 100% for PCR-positive patients. Within the group studied it was not possible to identify any clinical feature predictive of durable PCR-negativity. We believe that these findings could prompt the design of prospective studies to evaluate if the treatment of molecular disease can extend remission duration and survival.

Original languageEnglish
Pages (from-to)1927-1929
Number of pages3
JournalBlood
Volume102
Issue number5
DOIs
Publication statusPublished - Sep 1 2003

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this